



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

**First published:** June 30, 2015

**Last updated:** March 1, 2019

## **Guidelines for Manuscript Preparation and Submission: Case Control Study**

**Core tip:** These *Case Control Study* articles are submitted by any author and are structured as the identification of person/s with a disease of interest and a control (comparison, referent) group without the disease, followed by a description of the relationship of an attribute of the disease and its examination by comparative analysis of diseased *vs* non-diseased persons, with regard to the frequency or levels of the attribute in each group.

You can use the following checklist to help you fulfill the requirements for manuscript submission.

### **1 FIRST SECTION OF WRITING REQUIREMENTS YES or NO**

- 1.1 Title [      ]
- 1.2 Authorship [      ]
- 1.3 Institution [      ]
- 1.4 ORCID number [      ]
- 1.5 Supportive foundations [      ]
- 1.6 STROBE Statement [      ]
- 1.7 Corresponding author [      ]
- 1.8 Abstract [      ]



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

1.9 Key words [      ]

1.10 Core tip [      ]

## **2 SECOND SECTION OF WRITING REQUIREMENTS YES or NO**

2.1 Main text [      ]

2.2 Biostatistics [      ]

2.3 Units [      ]

2.4 Illustrations [      ]

2.5 Tables [      ]

2.6 Notes in illustrations and tables [      ]

2.7 Abbreviations [      ]

2.8 Italics [      ]

2.9 Acknowledgments [      ]

2.10 References [      ]

## **3 ETHICS POLICIES/STATEMENTS YES or NO**

3.1 Institutional review board [      ]

3.2 Informed consent [      ]

3.3 Conflict-of-interest [      ]

## **4 LANGUAGE EDITING FOR MANUSCRIPTS SUBMITTED BY NON-NATIVE SPEAKERS OF ENGLISH YES or NO**

## **5 COPYRIGHT LICENSE AGREEMENT YES or NO**

## **6 STEPS FOR SUBMITTING MANUSCRIPTS YES or NO**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **1 FIRST SECTION OF WRITING REQUIREMENTS**

All contributions should be written in English; the authors may use either UK or US English language, but the chosen English language usage must be consistent throughout the document. All articles must be prepared with Word-processing Software, using 12 pt Book Antiqua font and 1.5 line spacing with ample margins. Required information for each of the manuscript sections is as follows:

**1.1 Title.** The title should be no more than 12 words. The title should summarize the core content of the manuscript, so that the reader may readily understand the key concepts and important findings presented within. This type of succinct and impactful statement will serve to catch readers' attention and stimulate their interest in reading the abstract and/or downloading the full paper. It is also strongly recommended that the title include one or two of the key words associated with the manuscript's topical content, to facilitate the paper being readily found by electronic searches of public databases, such as Google or PubMed. Finally, a succinct and impactful title will include minimal nonfunctional words, such as "a", "an", "the", "roles of", and will avoid non-standard abbreviations.

**1.2 Authorship.** Authorship credit should be given in accordance with the standard proposed by the International Committee of Medical Journal Editors (ICMJE) (<http://www.icmje.org/>). Specifically, authorship is merited by (1) substantial contributions to conception and design of the study, acquisition of data, or analysis and interpretation of data; (2) drafting the article or making critical revisions related to important intellectual content of the manuscript; and (3) final approval of the version of the article to be published. Authors should meet conditions 1, 2 and 3. Designation of co-first authors and co-corresponding authors is not permitted. Author names



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

(unabbreviated) should be given as first name, middle name (acronym, with no period), and family (sur)name, and typed in bold with the first letter capitalized; a hyphen should be included between the syllables of Chinese names. For example, **Jason Lamontagne, Laura F Steel, Paul V Harper Jr, Bo Yuan, and Wei-Hong Tang.**

**1.3 Institution.** Author names (unabbreviated) should be given first as first name, middle name (acronym, with no period), and family (sur)name, and typed in bold with the first letter capitalized, with a hyphen included between the syllables of Chinese names, followed by the complete name of the affiliated institution, city, province/state, postcode, and country typed in non-bold. For example, **Xu-Chen Zhang, Li-Xin Mei,** Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. In the case that multiple authors represent a single institution, the authors will be listed together for that institution; for example, **Giuseppe Losurdo, Domenico Piscitelli, Antonio Giangaspero, Mariabeatrice Principi, Francesca Buffelli, Floriana Giorgio, Lucia Montenegro, Claudia Sorrentino, Annacinzia Amoroso, Enzo Ierardi, Alfredo Di Leo,** Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy. In the case that one author represents multiple institutions, the institutions will be listed separately; for example, **Jun Wen,** Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China  
**Jun Wen,** Department of General Surgery, The Third People's Hospital of Chengdu, Chengdu 610031, Sichuan Province, China

**1.4 ORCID number.** ORCID provides a persistent digital identifier that distinguishes you from every other researcher and, through integration in key research workflows such as manuscript and grant submissions, supports automated linkages between you



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

and your professional activities, thereby ensuring that your work is recognized. Please visit the ORCID website at <https://orcid.org/> for more information. All authors must provide their personal ORCID registration number. For example, Marcos Pasarín (0000-0002-4122-1235); Juan G Abraldes (0000-0002-4392-660X); Eleonora Liguori (0000-0002-0244-927X); Beverley Kok (0000-0002-1727-5030); Vincenzo La Mura (0000-0003-4685-7184).

**1.5 Supportive foundations.** The approved grant application form(s) will be released online, together with the manuscript in order for readers to obtain more information about the study and to increase the likelihood of subsequent citation. Our purpose of publishing the approved grant application form(s) is to promote efficient academic communication, accelerate scientific progress in the related field, and improve productive sharing of research ideas.

**Supportive foundation acknowledgment:** The complete name(s) of supportive foundation(s) and identification number(s) of grants or other financial support will be provided on the title page of all submitted manuscripts using the following format: **Supported by** the National Natural Science Foundation of China, No. 30224801.

**1.6 STROBE Statement.** In order to improve the quality of Case Control study manuscripts, authors should download and complete the 'STROBE Statement – checklist of items' to ensure that the manuscript meets the requirements of the STROBE Statement. Authors must state on the title page of the manuscript that the guidelines of the STROBE Statement have been adopted (see below). Authors must upload the PDF version of the completed checklist to the system.



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

**Sample wording:** The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

**1.7 Corresponding author.** Only one corresponding author is allowed. Designation of co-corresponding authors is not permitted. The corresponding author's contact information should be provided in the following format: Author names (unabbreviated) should be followed by the author's title in bold, and the affiliation, complete name of institution, present address, city, province/state, postcode, country, and E-mail typed in non-bold. All the letters in the E-mail address should be typed in lowercase, and separated from the country by a period and a space. For example, **Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief, Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, 5901 E Seventh St, Long Beach, CA 90822, United States.** [astarnaw@uci.edu](mailto:astarnaw@uci.edu)

**1.8 Abstract.** An informative, structured abstract of no less than 350 words should accompany each manuscript. Abbreviations should be avoided, but if used should be spelled out at first mention. The 5 sections of the structured abstract are: Background, Aims, Methods, Results, and Conclusion. Each section should adhere to the word count thresholds (indicated in parentheses) and the content guidelines below:

**BACKGROUND** (no more than 100 words)

This section should clearly describe the rationale for the study. It should end with a statement of the specific study hypothesis.

**AIM** (no more than 20 words)



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

The purpose of the study should be stated clearly, with no or minimal background information, following the format of: "To investigate/study/determine..."

**METHODS** (no less than 80 words)

This section should describe the materials and methods used for all of the data presented in the preceding Results section of the abstract. This information should include the following details, as applicable: basic study design (*e.g.*, randomized controlled trial, cross sectional study, cohort study, case series, *etc.*); setting, please specify study location (*e.g.*, primary or tertiary care setting, hospital, general community, *etc.*); number of participants and how they were selected; intervention, the method of administration and the duration.

**RESULTS** (no less than 120 words)

This section should describe the key findings of the study, including absolute values and risk differences. *P* values should be presented where appropriate. You must provide relevant data to illustrate how the statistical values were obtained (*e.g.*,  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ).

**CONCLUSION** (no more than 30 words)

This section should succinctly and cogently present the findings and implications that are within the scope of the data you have presented in the preceding Results section of the abstract. You should state only conclusions that are directly supported by the evidence presented and the implications of the findings presented. This section should be written in the present tense.

**1.9 Key words.** Please list 5-10 key words for each paper, which reflect the content of the



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

study and are selected mainly from the meSH Tree. Each key word is to be typed with the first letter capitalized, and separated by a semicolon, with no period at the end; for example, Colorectal cancer; Epigenetic analysis

**1.10 Core tip.** Please write a summary of no more than 100 words to present the core content of your manuscript, highlighting the most innovative and important findings and/or arguments. The purpose of the Core Tip is to attract readers' interest for reading the full version of your article and increasing the impact of your article in your field of study.

## **2 SECOND SECTION OF WRITING REQUIREMENTS**

**2.1 Main text.** The main text contains Introduction, Materials and methods, Results, Discussion, Acknowledgments, and References.

**2.2 Biostatistics.** Any manuscript describing a study (basic research and clinical research) that used biostatistics must include a statement in the Materials and Methods section affirming that the statistical review of the study was performed by a biomedical statistician. Statistical review is performed before the submission or after peer-review. The author invites an expert in Biomedical Statistics to evaluate the statistical method(s) used in the study, including but not limited to the *t*-test (group or paired comparisons), chi-square test, riddit, probit, logit and regression (linear, curvilinear, or stepwise) modeling, correlation, analysis of variance, and analysis of covariance. The review by the biomedical statistician is conducted with respect to the following points: (1) Statistical methods are adequately and appropriately described when they are used to verify the results; (2) Statistical techniques are suitable or correct, and compliant with the following Baishideng Publishing Group (BPG) directives; (3) Only homogeneous data can be





**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

averaged. Standard deviations are preferred to standard errors. The number of observations and subjects ( $n$ ) is given. Losses in observations, such as drop-outs from the study, are reported; (4) Values, such as ED50, LD50, and IC50, have the 95% confidence limits calculated and have been compared by weighted probit modeling (using the functions described by Bliss and Finney); and (5) The word “significantly” is replaced by its synonyms (if it indicates extent) or the  $P$  value (if it indicates statistical significance). Statistical data should be expressed as mean  $\pm$  SD or mean  $\pm$  SE. Common statistical expressions are identified as:  $t$ -test as  $t$ ;  $F$ -test as  $F$ ; chi-square test as  $\chi^2$ ; relative coefficient as  $r$ ; degree of freedom as  $df$ ; number of samples as  $n$ ; and probability as  $P$ .

**Sample wording:** The statistical methods of this study were reviewed by [name(s) of individual(s)] from [name(s) of organization(s)]...

If a biostatistics editor is employed by the authors, the person’s name (first name and family (sur) name), qualifications, and contact information must be submitted to the editorial office in the form of a letter of confirmation of service. If the biostatistics editing was performed by a commercial service provider, the company’s name and contact information, including URL and E-mail or phone number, must be submitted to the editorial office in the form of a letter of confirmation of service. The letters of confirmation of service must include the corresponding author’s name (first name and family (sur) name) and contact information (E-mail and phone number), and the manuscript title.

**2.3 Units.** Use SI units. For example: body mass,  $m$  (B) = 78 kg; blood pressure,  $p$  (B) = 16.2/12.3 kPa; incubation time,  $t$  (incubation) = 96 h; blood glucose concentration,  $c$  (glucose) =  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration,  $p$  (CEA) = 8.6-24.5 g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise, for 40 g/L formaldehyde, not



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23,243,641 (*i.e.*, 23 million, 243 thousand, and 641) should be written as 23243641, with no commas or spaces. The format for how to accurately write common units and quantities can be found at: <https://www.wjgnet.com/bpg/gerinfo/189>.

**2.4 Illustrations.** Figures must be presented in the order that they appear in the main text of the manuscript (numbered as 1, 2, 3, *etc.*). All figures must have a detailed figure legend that provides a clear and comprehensive description of the information presented in the figure, so that the reader can understand without having to refer back to any other portion of the manuscript.

It is necessary to keep all elements compiled in a line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend text rather than on the bar itself. Figure file names should identify the figure and panel. Avoid layering type directly over shaded or textured areas in the figure. Uniform presentation should be used for figures showing the same or similar contents; for example, “**Figure 1 Pathological changes of atrophic gastritis after treatment.** A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...”.

**2.5 Tables.** Tables must be presented in the order that they appear in the main text of the manuscript (numbered as 1, 2, 3, *etc.*). A brief, one-line title must be provided for each table. Detailed legends should not be included under tables, instead having the information presented in the main text where applicable; the information should complement, but not duplicate the text. Use one horizontal line under the title, a second under the column headings, and a third below the last row of the Table (being above any footnotes). Vertical lines and italics should be omitted.

Please note that tables embedded as Excel files within the manuscript are NOT



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

acceptable. Tables made in Excel should be copied and pasted into the manuscript Word file. All tables will be located at the very end of your article document, following the figures. Any tables submitted that are longer/larger than two pages will be published as online-only supplementary material.

Tables must be primarily cell-based and fully editable. Do not use the following to organize data or structure the table: (1) Returns (“Enter” key); (2) Tabs; (3) Spaces; (4) Colored text; (5) Cell shading; and (6) Cells within cells. The software used should be Word (preferred) or Excel. BPG does not allow for graphics, boxes or embedded tables to appear in the main body of the manuscript.

**2.6 Notes in illustrations and tables.** Data with statistical significance in a figure or table should be denoted using superscripted alphabetical lettering, such as <sup>a</sup>*P* < 0.05 and <sup>b</sup>*P* < 0.01. If there are other series of *P* values, the alphabetical subscripted denotation format is continued, such as <sup>c</sup>*P* < 0.05 *vs* control, <sup>d</sup>*P* < 0.01 *vs* control, <sup>e</sup>*P* < 0.05 *vs* group A, and <sup>f</sup>*P* < 0.01 *vs* group B. Data that are not statistically significant should not be denoted, *i.e.*, *P* > 0.05 is not an allowed denotation.

Other notes in tables or under illustrations should be expressed as F<sup>1</sup>, F<sup>2</sup>, F<sup>3</sup>, or sometimes as other superscripted symbols (Arabic numerals). In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a specified sequence.

**2.7 Abbreviations.** Standard abbreviations should be defined in the abstract and in the main body of the manuscript upon first mention in the text. In general, terms should not be abbreviated unless they are used three times or more and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, and mAb, do not need to be defined and can be used directly.

**2.8 Italics.** Quantities: *t*, time or temperature; *c*, concentration; *A*, area; *l*, length; *m*, mass; *V*, volume. Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc. Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kbo I*, *Kpn I*, etc. Biological nomenclature: *H. pylori*, *E. coli*, etc. Latin terms: *i.e.*, *e.g.*, *via*, etc.

**2.9 Acknowledgments.** Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

**2.10 References.** Case control study should be composed of detailed contents, comparisons, and evaluations in relation to other published relevant articles, and an in-depth discussion. Please don't use informal publications. For seminal references, however, the publication date is not strictly limited. You should always cite references that are relevant to your article. Citing more than five references in a single citation, even when separated by a hyphen, should be avoided; for example [1-6], [2-14], and [1,3,4-10,22] are all considered inappropriate reference citations. Moreover, authors should not cite their own unrelated published articles. Citation of references not indexed on PubMed is discouraged, but if a reference that is not indexed by PubMed is necessary, you must provide BPG with a printed copy of the first page of the full article. Please update the format of all the references according to the Format for references guidelines. The accuracy of the information of journal citations is very important. We will interlink all references with DOIs in an XML file, so that readers can immediately access the abstracts



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

of cited articles online.

This section includes Coding system, PMID and DOI, Style for journal references, Style for book references, and Format for references (Examples). Specific requirements are as follows:

### (1) *Coding system*

The author should number the references in Arabic numerals according to the citation order in the text. The reference numbers will be superscripted in square brackets at the end of the sentence with the citation content or after the cited author's name, with no spaces. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>." If references are cited directly in the text, they should be included with the direct citation content within the text; for example, "From references<sup>[19,22-24]</sup>, we know that...". Before submitting your manuscript, please ensure that the order of citations in the text is the same as in the references section, and also ensure the spelling accuracy of the authors' names. Do not list the same citation twice (*i.e.*, with two different numbers).

### (2) *PMID and DOI*

Please provide the PMID number, which is the serial number that roots the abstract for that publication into the PubMed index, and the CrossRef DOI<sup>®</sup> (Digital Object Identifier) name, which is a unique string created to identify a piece of scholarly content in the online environment for each reference in the References section. The PMID number can be found at <http://www.ncbi.nlm.nih.gov/pubmed> and the DOI name at <http://www.crossref.org/SimpleTextQuery/>. The numbers will be used in the electronic (E)-version of the manuscript.

### (3) *Style for journal references*

For authors' names, the name of the first author should be typed in bold letters; the family (sur)name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. For example, an article by Lian-Sheng Ma and Bo-Rong Pan will be written as Ma LS and Pan BR. The title of the cited article will



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

be written in sentence case. The journal title will be written in its abbreviated form (as shown in PubMed) in italics and followed by the article publication information (not italicized), including the publication date, volume number (in bold numbers), and start page through end page (separated by a hyphen, with no space). The PMID and DOI will follow this information and be written as [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

#### (4) *Style for book references*

For the authors' names, the name of the first author should be typed in bold letters. The family (sur)name of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. The book title will follow the authors' names and not be italicized. The publication information will follow, written as punctuated here: publication number, publication place: publication press, year: start page-end page.

BPG uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also referred to as the "Vancouver" style. Example formats are listed below. Additional examples are in the [ICMJE sample references](#).

Journal name abbreviations should be those found in the [National Center for Biotechnology Information databases](#).

#### **PRINT JOURNALS**

**English-language journal articles (list all authors and include the PMID and DOI, where applicable):**

**1 Ma L, Chua MS, Andrisani O, So S.** Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives. *World J Gastroenterol* 2014; 20: 333-345 [PMID: 24574704 PMCID: PMC3923010 DOI: 10.3748/wjg.v20.i2.333]

**Chinese-language journal articles (list all authors and include the PMID and DOI, where applicable):**

**2 Zhang ZM, Deng H, Zhang C, Yu HW, Liu Z, Liu LM, Wan BJ, Zhu MW.** Strategies for



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

diagnosis and treatment of benign and malignant colorectal obstruction. *Shijie Huaren Xiaohua Zazhi* 2017; 25: 2597-2604 [DOI: 10.11569/wcjd.v25.i29.2597]

**In press articles:**

3 **Sipos F, Constantinovits M, Valcz G, Tulassay Z, Múzes G.** Association of hepatocyte-derived growth factor receptor/caudal type homeobox 2 co-expression with mucosal regeneration in active ulcerative colitis. *World J Gastroenterol* 2015; In press

**Organization as author:**

4 **Diabetes Prevention Program Research Group.** Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462]

**Both individual authors and an organization as author:**

5 **Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group.** Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764]

**No author given:**

6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303]

**Volume with supplement:**

7 **Geraud G, Spierings EL, Keywood C.** Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325]

**Issue with no volume:**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900]

**No volume or issue:**

9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

**BOOKS**

**Individual author(s):**

10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

**Chapter in a book (list all authors):**

11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

**Author(s) and editor(s):**

12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

**CONFERENCE-RELATED ARTICLES**

**Conference proceedings:**

13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56





**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

#### **Conference papers:**

14 **Christensen S, Oppacher F.** An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### **ELECTRONIC JOURNALS**

##### **Electronic journals (list all authors):**

15 Huynen MMTE, Martens P, Hilderink HBM. The health impacts of globalisation: a conceptual framework. *Global Health*. 2005; 1: 14. Available from: <https://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603-1-14> doi.org/10.1186/1744-8603-1-14 [PMID: 21501219 DOI: 10.1186/1744-8603-1-14]

#### **PATENTS**

##### **Patents (list all authors):**

16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### **CLINICAL TRIAL**

17 **Cannon R.** Riloncept to improve artery function in patients with atherosclerosis. [accessed 2015 Apr 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <http://clinicaltrials.gov/show/NCT00417417> ClinicalTrials.gov Identifier: NCT00417417

#### **DEPOSITED ARTICLES (preprints, e-prints, or arXiv)**

18 **Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et al.** Amino acid



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

metabolism conflicts with protein diversity; 1991. Preprint. Available from: arXiv:1403.3301v1. Cited 17 March 2014.

#### **PUBLISHED MEDIA** (print or online newspapers and magazine articles)

**19 Fountain H.** For Already Vulnerable Penguins, Study Finds Climate Change Is Another Danger. The New York Times. 29 Jan 2014. Available from: <http://www.nytimes.com/2014/01/30/science/earth/climate-change-taking-toll-on-penguins-study-finds.html> Cited 17 March 2014.

#### **NEW MEDIA** (blogs, web sites, or other written works)

**20 Allen L.** Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. In: PLOS Blogs [Internet]. San Francisco: PLOS 2006 - . [about 2 screens]. Available from: <http://blogs.plos.org/plos/2010/09/announcing-plos-blogs/>.

#### **MASTERS' THESES OR DOCTORAL DISSERTATIONS**

**21 Wells A.** Exploring the development of the independent, electronic, scholarly journal. M.Sc. Thesis, The University of Sheffield. 1999. Available from: <http://cumincad.scix.net/cgi-bin/works/Show?2e09>

#### **DATABASES AND REPOSITORIES** (Figshare or arXiv)

**22 Roberts SB.** QPX Genome Browser Feature Tracks; 2013 [cited 2013 Oct 5]. Database: figshare [Internet]. Available from: [http://figshare.com/articles/QPX\\_Genome\\_Browser\\_Feature\\_Tracks/701214](http://figshare.com/articles/QPX_Genome_Browser_Feature_Tracks/701214)

#### **MULTIMEDIA** (videos, movies, or TV shows)

**23 Hitchcock A,** producer and director. Rear Window [Film]; 1954. Los Angeles: MGM.



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

### 3 ETHICS POLICIES/STATEMENTS

**3.1 Institutional review board.** Any article describing a study (basic research and clinical research) involving human and/or animal subjects is required to have the institutional review board (IRB) name, whether institutional (part of the author(s)' academic/medical institution, such as the Oak Grove Children's Hospital Institutional Review Board) or commercial/independent/private (contracted for-profit organizations, such as the ClinicCare Coalition for Human Rights Institutional Review Board), stated explicitly on the title page.

**3.2 Informed consent.** Any research article describing a study (clinical research and case report) involving humans should contain a statement in the title page clearly stating that all involved persons (subjects or legally authorized representative) gave their informed consent (written or verbal, as appropriate) prior to study inclusion. In general, the BPG requires that any and all details that might disclose the identity of the subjects under study should be omitted or anonymized. In the rare situation that a study participant's identifiable information is crucial to the case presentation, the statement of informed consent is absolutely necessary, unless the participant is deceased.

**3.3 Conflict-of-interest.** A conflict-of-interest statement is required for all article and study types. In the interests of transparency and helping reviewers to assess any potential bias in a study's design, interpretation of its results, or presentation of its scientific/medical content, the BPG requires all authors of each paper to declare on the title page any conflicting interests (including but not limited to commercial, personal, political, intellectual, or religious interests) that are related to the work submitted for consideration of publication.



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

#### **4 LANGUAGE EDITING FOR MANUSCRIPTS SUBMITTED BY NON-NATIVE SPEAKERS OF ENGLISH**

We will, with the right attitude and approach, cooperate with authors who are not native speakers of English so that they may successfully complete the final publication of their manuscripts. Quality control of a manuscript's language is not negotiable with the BPG or any of its journals. The language of the manuscript must meet the requirements of academic publishing.

For manuscripts submitted by non-native speakers of English, the authors are required to provide a language editing certificate which will serve to verify that the language of the manuscript has reached grade A. Before the manuscript is finally published, the language of the manuscript must also pass the proofreading test by an English language editor (native or non-native) who will be designated at the discretion of the journal's editorial office.

We strongly recommend that authors use language editing services provided by the following biomedical editing companies, based on their good reputation and reliable quality:

**Filipodia Publishing, LLC:** <http://www.filipodia.com/>

**MedE Editing Group:** <http://meditorexpert.com>

**American Journal Experts:** <http://www.aje.com>

**Nature Publishing Group Language Editing:** <http://languageediting.nature.com>

These companies often provide several different types of language editing services, typically including proofreading, standard editing, extensive editing, and rewriting. We strongly recommend that authors use the extensive editing service so as to completely address the language problems of the manuscript. For example, extensive editing will involve editing the manuscript for proper grammar and spelling and the correct usage of articles, prepositions, conjunctions, abbreviations, punctuation, italic font of Latin words,



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

biomedical terms, tenses, active voice and passive voice, and sentence structure, as well as checking of the academic rules and norms, and for scientific misconduct, details of the materials and methods, manuscript integrity, manuscript title appropriateness, logical organization of the Introduction, Results and Discussion sections, and image features.

After authors confirm the revisions made during the professional editing process, the companies listed above should provide authors with an official manuscript language editing certificate, through which the company guarantees that the language of the manuscript has reached grade A.

## **5 COPYRIGHT LICENSE AGREEMENT**

Application for copyright license agreement will be made by written declaration of and attestation to the following:

- (1) The copyright on any open access article in a journal published by BPG is retained by the author(s).
- (2) Author(s) grant BPG the license to publish the article and identify itself as the original publisher.
- (3) Author(s) grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details, and publisher are identified.

## **6 STEPS FOR SUBMITTING MANUSCRIPTS**

**Step 1: Create an account for correspondence.** Please open the F6Publishing page (<https://www.f6publishing.com/Forms/Main/Login.aspx>) and click 'Corresponding Author Register' to provide the corresponding author's Personal Information and Institution-Related Information. When the complete information has been typed in, please click the Submit button, and the system will automatically send you a user name and password *via* e-mail.



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

**Note:** All authors' ORCID numbers need to be submitted when creating an account for correspondence. To obtain an ORCID number, please visit: <https://orcid.org/>.

**Step 2: Login to F6Publishing.** After receipt of the user name and password for the corresponding author, please login to F6Publishing by clicking 'Author Login'. After login, click 'Start New Submission' and find the Manuscript General Information zone, in which the corresponding author should fill in the information for the fields of Journal, Manuscript Title, Country of Manuscript Source, Manuscript Source, Invited Manuscript ID, Funding Agency and Grant Number, Manuscript Scope, Specialty, Manuscript Type, Abstract, Keywords, Core Tip, and Cover Letter. After information in all fields is completed, click either 'Save & Continue' or 'Skip & Continue'. If you want to modify the information at this step, please click 'Go Back'.

**Note:** In the F6Publishing system, the \* denotes Required Fields.

**Step 3: All author list.** The corresponding author submits the information for all authors in an order based on their contributions to the manuscript. Co-first authors and co-corresponding authors are not allowed. Personal Information and Institution-Related Information should be submitted for each author. The corresponding author should ensure that all information provided for the Institution-Related Information and Correspondence To fields is correct.

**Note:** Please check the box in front of 'Is Corresponding Author' to confirm and formally attest to the corresponding author status for the person providing the information.



**Step 4: Upload manuscript and relevant files.** First, for all manuscripts involving human studies and/or animal experiments, author(s) must submit the related formal ethics documents that were reviewed and approved by their local ethical review committee. This is mandatory and is one of the determining factors for whether or not the manuscript will be sent for peer review. If human and animal studies received waiver of the approval requirement from the ethics committee, the author(s) must provide an official statement to this effect generated by the ethics committee. The ethics and relevant document(s) required for the Case Control Study and the methods for uploading these documents are described below:

Manuscript Type	Name(s) of ethics and relevant documents required	Sample
<p><b>Case Control Study</b></p>	<p><b>(1 of 6) Institutional Review Board Approval Form or Document</b></p> <p>Please upload the primary version (PDF) of the Institutional Review Board’s official approval in the official language of the authors’ country to the system; for example, authors from China should upload the Chinese version of the document, authors from Italy should upload the Italian version of the document, authors from Germany should upload the Deutsch version of the document, and authors from the United States and the United Kingdom should upload the English version of the document, <i>etc.</i></p>	<p><a href="#">Download</a></p>



	<p>(2 of 6) <b>Signed Informed Consent Form(s) or Document(s)</b></p> <p>Please upload the primary version (PDF) of the Informed Consent Form that has been signed by all subjects and investigators of the study, prepared in the official language of the authors' country to the system; for example, authors from China should upload the Chinese version of the document, authors from Italy should upload the Italian version of the document, authors from Germany should upload the Deutsch version of the document, and authors from the United States and the United Kingdom should upload the English version of the document, <i>etc.</i></p>	<p><a href="#">Download</a></p>
	<p>(3 of 6) <b>Conflict-of-Interest Disclosure Form</b></p> <p>Please download the fillable ICMJE Form for Disclosure of Potential Conflicts of Interest (PDF), fill it in, and then upload the completed PDF version to the system.</p> <p><b>Note:</b> The Corresponding Author is responsible for filling out a Conflict-of-Interest Disclosure Form.</p>	<p><a href="#">Download</a></p>
	<p>(4 of 6) <b>Copyright License Agreement</b></p> <p>Please upload the PDF version of the Copyright License Agreement Form that has been signed by all authors.</p>	<p><a href="#">Download</a></p>





	<p>(5 of 6) <b>Biostatistics Review Certificate</b></p> <p>Please upload the PDF version of a statement affirming that the statistical review of the study was performed by a biomedical statistician to the system.</p>	<p><a href="#">Download</a></p>
	<p>(6 of 6) <b>STROBE Statement</b></p> <p>In order to improve the quality of Case Control study, Observational study and Retrospective Cohort study manuscripts, authors should:</p> <ol style="list-style-type: none"> <li>1) Download the 'STROBE Statement – checklist of items that should be included in reports of observational studies' before the peer review process;</li> <li>2) Complete the checklist to ensure that the manuscript meets the requirements of the STROBE Statement;</li> <li>3) State on the title page of the manuscript that the guidelines of the STROBE Statement have been adopted;</li> <li>4) And, upload the PDF version of the completed checklist to the system.</li> </ol>	<p><a href="#">Download</a></p>

Click the radio button (left screen) for the file type you will upload. Then, select the corresponding file(s) you will upload by clicking the 'Browse' button (right screen) and choosing the file from your computer system. The file(s) you have selected for uploading will appear in the 'Uploaded Files' box. The file uploading will be initiated by clicking the



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

'Submit' button (right screen). All tables and images (figures) MUST be EMBEDDED in the manuscript file; there is not a separate submission step for the tables and figures.

**Note:** After the manuscript and related documents are uploaded, click the 'Submit' button to submit all documents. Once the documents are submitted, no further changes are allowed.

After the submission, all authors will receive an e-mail notification of receipt of the manuscript. If authors have not received the manuscript receipt or if they encountered technical problems when uploading the manuscript, please contact the F6Publishing team *via* the Help Desk (<https://www.f6publishing.com/Helpdesk>) or by sending an e-mail to [submission@wjgnet.com](mailto:submission@wjgnet.com).